{"id":566571,"date":"2026-09-09T23:00:00","date_gmt":"2026-09-09T21:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/la-therapie-personnalisee-a-lere-des-medicaments-cibles\/"},"modified":"2026-09-21T10:59:29","modified_gmt":"2026-09-21T08:59:29","slug":"la-therapie-personnalisee-a-lere-des-medicaments-cibles","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/la-therapie-personnalisee-a-lere-des-medicaments-cibles\/","title":{"rendered":"La th\u00e9rapie personnalis\u00e9e \u00e0 l’\u00e8re des m\u00e9dicaments cibl\u00e9s"},"content":{"rendered":"\n

Lors du congr\u00e8s annuel de l\u2019ASCO de 2026, de nouvelles donn\u00e9es concernant l\u2019utilisation du pirtobrutinib chez des patients n\u2019ayant jamais re\u00e7u de traitement et atteints de leuc\u00e9mie lympho\u00efde chronique ont \u00e9t\u00e9 pr\u00e9sent\u00e9es. Les r\u00e9sultats des \u00e9tudes de phase III BRUIN CLL-313 et BRUIN CLL-314 fournissent un aper\u00e7u actualis\u00e9 de l’efficacit\u00e9 et de la s\u00e9curit\u00e9 de l’inhibition non covalente de la BTK en premi\u00e8re intention.<\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Lors du congr\u00e8s annuel de l\u2019ASCO de 2026, de nouvelles donn\u00e9es concernant l\u2019utilisation du pirtobrutinib chez des patients n\u2019ayant jamais re\u00e7u de traitement et atteints de leuc\u00e9mie lympho\u00efde chronique ont……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":566578,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Leuc\u00e9mie lympho\u00efde chronique (LLC)","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11549,11527,11373,11389,11535],"tags":[102063,102041,102038,102062,102039,101584,102060,102058,102047,102067,102069,102042,102065,85922,102040,102068,102054,102052,102064,92847,55814,102056,90046,102049,102051,19432,102066],"powerkit_post_featured":[],"class_list":["post-566571","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-etudes","category-hematologie","category-oncologie","category-rapports-de-congres","tag-aberrations-du-gene-tp53","tag-blocage-reversible-du-btk","tag-bruin-cll-314","tag-caryotype-complexe","tag-cll-sll","tag-congres-annuel-de-lasco-2026","tag-del11q","tag-del17p","tag-duree-de-reponse-dor","tag-effets-indesirables-cardiovasculaires","tag-facteurs-de-risque-moleculaires","tag-inhibiteurs-covalents-de-la-btk","tag-inhibiteurs-de-bcl2","tag-inhibiteurs-de-btk","tag-inhibition-non-covalente-de-la-btk","tag-interruptions-de-traitement","tag-mutation-c481s","tag-mutations-de-resistance","tag-mutations-du-gene-notch1","tag-pirtobrutinib","tag-profil-de-securite","tag-statut-ighv","tag-survie-sans-progression-pfs","tag-taux-de-reponse-global-orr","tag-traitement-de-la-llc","tag-traitement-de-premiere-ligne","tag-voie-de-signalisation-bcr","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-16 00:42:01","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":566580,"slug":"la-terapia-personalizzata-nellera-dei-farmaci-mirati","post_title":"La terapia personalizzata nell\u2019era dei farmaci mirati","href":"https:\/\/medizinonline.com\/it\/la-terapia-personalizzata-nellera-dei-farmaci-mirati\/"},"pt_PT":{"locale":"pt_PT","id":566594,"slug":"terapia-individualizada-na-era-dos-principios-ativos-direcionados","post_title":"Terapia individualizada na era dos princ\u00edpios ativos direcionados","href":"https:\/\/medizinonline.com\/pt-pt\/terapia-individualizada-na-era-dos-principios-ativos-direcionados\/"},"es_ES":{"locale":"es_ES","id":566561,"slug":"terapia-individualizada-en-la-era-de-los-farmacos-dirigidos","post_title":"Terapia individualizada en la era de los f\u00e1rmacos dirigidos","href":"https:\/\/medizinonline.com\/es\/terapia-individualizada-en-la-era-de-los-farmacos-dirigidos\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/566571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=566571"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/566571\/revisions"}],"predecessor-version":[{"id":566956,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/566571\/revisions\/566956"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/566578"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=566571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=566571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=566571"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=566571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}